Advertisement
Screener

SCIENTURE HOLDINGS, INC. (SCNX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.2 / 5 stars · 44/102 Roast Me

SCIENTURE HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

SCIENTURE HOLDINGS, INC. (SCNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-27.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2023-03-27

  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-03-31 was 0.00%.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
  • SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2021-12-310.00%
10-K · filed 2023-03-27
2021-09-300.00%
10-Q · filed 2021-10-25
2021-06-300.00%
10-Q · filed 2021-07-26
2021-03-310.00%
10-Q · filed 2021-04-26
2020-12-310.00%
10-K · filed 2022-03-28
2020-09-300.00%
10-Q · filed 2020-10-26
2020-06-300.00%
10-Q · filed 2020-07-27
2020-03-310.00%
10-Q · filed 2020-05-04
2019-12-310.00%
10-K · filed 2021-03-29
2019-09-300.00%
10-Q · filed 2019-10-28
2019-06-300.00%
10-Q · filed 2019-07-26
2018-12-310.00%
10-K · filed 2020-03-30
2017-12-310.00%
10-K · filed 2019-03-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
BIOVIE INC. (BIVI)United States$0.012B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33